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In recent years bisphosphonates have become important in the
management of cancer-induced bone disease and are now well
established in the management of patients with multiple myeloma
and bone metastases secondary to breast cancer (Paterson et al,
1993; Berenson et al, 1996; Hortobagyi et al, 1996; Diel
et al, 1998; McCloskey et al, 1998; Theriault et al, 1999).
Randomized controlled trials in patients with breast cancer have
demonstrated that clodronate and pamidronate reduce skeletal
morbidity and improve quality of life (Paterson et al, 1993;
Hortobagyi et al, 1996; Kanis et al, 1996). Furthermore, in the
adjuvant situation, studies with oral clodronate suggest that the use
of bisphosphonates in combination with chemotherapy or endo-
crine therapy may delay first recurrence in bone (Diel et al, 1998).
In addition, Diel et al have shown that treatment with oral clodro-
nate may be associated with reduced rates of visceral metastases
and improved survival compared with those receiving standard
antineoplastic therapy alone (Diel et al, 1998). However, the role
of bisphosphonates in the adjuvant setting remains to be clarified
as Saarto et al reported an increase in the frequency of bone and
visceral metastases with poorer survival in clodronate treated
patients when compared with control (Saarto et al, 2000). 
The mechanisms by which bisphosphonates elicit their anti-
resorptive activity are only now becoming clear. Recent data
suggest that bisphosphonates that are similar in structure to pyro-
phosphate, such as clodronate and etidronate, are metabolized to
cytotoxic analogues of ATP (Frith et al, 1997) and these analogues
are responsible for inhibiting osteoclast activity. In contrast,
nitrogen-containing bisphosphonates, which include pamidronate,
ibandronate, alendronate and zoledronic acid (Zometa®), induce
apoptosis in osteoclasts by inhibiting enzymes of the mevalonate
pathway and preventing the isoprenylation of small GTP-binding
proteins such as Ras and Rho (Hughes et al, 1995; Luckman et al,
1998). However, bisphosphonates have also been shown to have
effects on cells other than osteoclasts, including tumour cells.
Shipman et al have demonstrated that the nitrogen-containing
bisphosphonate, incadronate, could induce apoptosis of human
multiple myeloma cells in vitro (Shipman et al, 1997), an effect
that was mediated by inhibition of the mevalonate pathway
(Shipman et al, 1998). Studies have also suggested that bisphos-
phonates can inhibit the adhesion of breast cancer cells to bone
matrices (Van der Pluijm et al, 1996; Boissier et al, 1997;
Magnetto et al, 1999) and can enhance the ability of anti-
neoplastic agents to inhibit breast cancer cell invasion (Magnetto
et al, 1999). Thus, the demonstration that these compounds can
induce apoptosis in cells other than osteoclasts, and that the treat-
ment of patients with bisphosphonates may improve survival,
raises the intriguing possibility that bisphosphonates may also
have direct anti-tumour effects in breast cancer cells. The aim of
the present studies was to determine whether the third generation
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bisphosphonate zoledronic acid has direct anti-tumour effects on
breast cancer cells in vitro and, more importantly, whether 
zoledronic acid has additive or synergistic effects with anti-
neoplastic agents, such as paclitaxel, at clinically relevant
concentrations. 
MATERIALS AND METHODS 
Chemicals 
Zoledronic acid 1-hydroxy-2-[(1H-imidazol-1-yl) ethylidene]
bisphosphonic acid monohydrate was supplied as the hydrated
disodium salt by Novartis Pharma AG (Basel, Switzerland). A
stock solution was prepared in phosphate-buffered saline (PBS)
(pH 7.4) and filter-sterilized using a 0.22-mM filter (Gelman
Sciences, Northampton, UK). Farnesol (FOH) and geranylgeraniol
(GGOH) were purchased from Sigma Chemical Co (Poole, UK)
and American Radiolabeled Chemicals Inc (St Louis, MO),
respectively. Stock solutions were prepared in 100% ethanol. All
other chemicals, unless otherwise stated, were obtained from
Sigma Chemical Co. 
Cell culture 
The human breast carcinoma cell line MCF-7 was obtained from
the European Collection of Animal Cell Cultures (Salisbury, UK).
Professor R Nicholson (University of Cardiff, Wales, UK) kindly
provided the MDA-MB-231 human breast carcinoma cell line.
Cells were cultured in RPMI 1640 (Life Technologies, Inc,
Paisley, UK) supplemented with 10% FCS, 1 mM glutamine, 
1 mM sodium pyruvate and 1x MEM nonessential amino acids
(Life Technologies Inc). Cells were harvested using trypsin/ETDA
0.5%/0.2% (Life Technologies). 
Measurement of cell number 
MCF-7 and MDA-MB-231 breast cancer cells were plated at a
density of 5 ´ 104 cells ml–1 in 24-well plates in replicates of 4
wells per treatment and allowed to adhere and proliferate for 72
hours. Cells were then incubated with fresh media containing
increasing concentrations of zoledronic acid (0.1–100 mM) for 72
hours. In some studies, MCF-7 cells were seeded as described
above and incubated with 100 mM zoledronic acid for 24, 48, 72
and 96 hours. MCF-7 cells were also incubated with 100 mM
EDTA for 72 hours to determine the effects of calcium chelation
on cell number. In experiments to determine whether there was a
synergistic effect when paclitaxel and zoledronic acid were
combined, MCF-7 cells were incubated in the presence or
absence of 10 mM zoledronic acid and/or 2 nM paclitaxel acid for
a total of 72 hours. Cells were also incubated with increasing
concentrations of paclitaxel alone and in combination with
increasing concentrations of zoledronic acid for a total of 72
hours to enable the construction of isobolograms. In order to
assess the effects of acute exposure to zoledronic acid, MCF-7
cells were prepared as described above and incubated with or
without zoledronic acid for 2, 6 or 24 hours. The media was 
then replaced with fresh media without zoledronic acid and the
cells incubated for a total of 72 hours. In each experiment,
following incubation, cells were harvested, suspended in PBS and
cell number determined using a haemocytometer (Improved
Neubauer). 
Identification of apoptotic cells by examination of
nuclear morphology 
MCF-7 and MDA-MB-231 breast cancer cells were cultured as
described above for assessment of nuclear morphology with 4
replicates per treatment. Cells were incubated with zoledronic acid
as above, harvested, and fixed with 4% formaldehyde (v/v) in PBS
and cytospun onto glass slides. Nuclei were stained with 4¢-6-
diamidino-2-phenyl-indole (DAPI) at 2 mgm l –1 in PBS for 15
minutes and examined, using a DMRB fluorescence microscope
(Leica), for the characteristic changes of apoptosis (Wyllie et al,
1980). 
Identification of apoptotic cells by the in situ nick
translation assay 
MCF-7 and MDA-MB-231 breast cancer cells were seeded at 1 ´
105 cells ml–1 in 6-well plates, allowed to adhere and proliferate for
72 hours and then treated as described in the previous section. In
some experiments, MCF-7 cells were treated with 100 mM zole-
dronic acid in the presence or absence of mevalonate, 50 mM
farnesol or 50 mM geranylgeraniol, for 72 hours, in order to deter-
mine the effects of intermediates of the mevalonate pathway on
zoledronic acid-induced apoptosis. Cells were harvested, washed
in sterile PBS, fixed in 4% formaldehyde for 15 minutes on ice and
permeabilized by incubation with 100% ethanol overnight. To
label DNA strand breaks in apoptotic cells, the samples were incu-
bated at room temperature with a buffer containing 50 mM tris,
2.5 mM magnesium chloride, 10 mgm l –1 bovine serum albumen,
10 mM b-mercaptoethanol, 0.2 nM of unlabelled dATP, dGTP and
dCTP and 0.2 nM biotin-16-dUTP in the presence of 1 unit DNA
polymerase for 4 hours with intermittent gentle agitation
(Gorczyca et al, 1993). The cells were then washed in sterile PBS
and incubated with a second buffer containing 43 saline-sodium
citrate buffer (SSC), 0.1% Triton-X 100, 5% (w/v) fat-free
powdered milk and 1% (v/v) phycoerythrin-conjugated strepta-
vidin (DAKO) for 30 minutes at room temperature in the
dark. After washing with PBS, cells were analysed using flow
cytometry. 
Statistical analysis 
Results were expressed as mean ± SEM. The relationship between
the concentration of zoledronic acid, time of incubation with zole-
dronic acid, and effects on cell number and apoptosis were
analysed using the non-parametric Kruskal–Wallis Analysis by
Rank test. Experiments using the in situ nick translation assay
were performed with a single sample per treatment. These data
were therefore not analysed for statistical significance. All other
data were analysed using non-parametric Mann–Whitney U test.
All experiments were repeated on at least 2 separate occasions
unless specified otherwise. 
Isobologram analysis 
The isobologram method of analysis was used to assess whether
synergistic effects were seen when paclitaxel and zoledronic acid
were combined. This method allows the identification of interac-
tions between 2 drugs, regardless of mechanism of action of the
individual drug (Berenbaum, 1989; Greco et al, 1995). Dose-
response curves were plotted for the effects of paclitaxel and theeffects of zoledronic acid on MCF7 cell number. From these, the
combined drug IC75 values (75% of maximum effect, 25%
remaining) were determined for each curve. The ratio of the
combined drug IC75 to the IC75 value of each drug along was calcu-
lated and plotted as an isobologram (D/D75). This analysis was
repeated for the data obtained from experiments determining the
effect of paclitaxel and zoledronic acid on apoptosis. In this case,
IC5 values and the corresponding ratios (D/D5) were calculated
from the dose–response curves in order to maximize the number of
data points on the isobologram. 
RESULTS 
Zoledronic acid causes a reduction in breast cancer
cell number 
Treatment of MCF-7 breast cancer cells with increasing concentra-
tions of zoledronic acid for 72 hours caused a dose-dependent
decrease in cell number (Figure 1A) (P < 0.001). 0.1–1 mM zole-
dronic acid had little effect on the number of MCF-7 cells. In
contrast, zoledronic acid at 10 and 100 mM caused a significant
reduction in the proportions of MCF-7 cells (49.54 ± 5.43% and
23.55 ±5.43% of control, respectively) (P < 0.05). Zoledronic acid
had little effect on MDA-MB-231 cells at concentrations of 0.1–
10 mM, whereas the 100 mM concentration resulted in a significant
reduction in cell number (25.33 ± 6.0% of control) (P < 0.05).
Treatment of breast cancer cells with 100 mM zoledronic acid for
increasing periods of time resulted in a 63.5% reduction in MCF-7
cell number at 72 hours (6.8 ± 5.3 ´ 104 vs 18.6 ± 3.2 ´ 104) and an
87.1% reduction at 96 hours (3.81 ± 1.9 ´ 104 vs 29.6 ± 4.5 ´ 104)
(P < 0.05 in each case) (Figure 1B). Incubation of MCF-7 cells
with 100 mM EDTA resulted in a small but significant reduction in
cell number when compared with control (16.08 ´ 104 ± 4.2 vs
24.52 ´ 104 ± 4.3). However, treatment with zoledronic acid
caused a greater reduction in cell number (7.00 ´ 104 ± 1.5 vs
24.52 ´ 104 ± 4.3) and this was significantly lower than that caused
by EDTA (P < 0.05 when zoledronic acid was compared to EDTA)
(Table 1). 
Zoledronic acid induces apoptosis of breast cancer
cells 
Treatment of MCF-7 and MDA-MB-231 cells with zoledronic
acid caused an increase in the proportion of cells with nuclear
morphology characteristic of apoptosis. These characteristics
included nuclear fragmentation, chromatin condensation and the
formation of dense, rounded apoptotic bodies (Figure 2).
Treatment of cells with increasing concentrations of zoledronic
acid (0.1–100 mM) resulted in a dose-dependent increase in the
proportion of cells undergoing apoptosis (P < 0.005).
Concentrations of 0.1 and 1 mM zoledronic acid had little effect
on MCF-7 cell apoptosis. In contrast, treatment with 10 mM zole-
dronic acid resulted in a greater than 4-fold increase in MCF-7 cell
apoptosis (431.26 ± 32.21% of control) whereas the 100 mM
concentration induced a 6-fold increase in the proportion of apop-
totic cells (652.54 ± 71.49% of control) (Figure 2C). Treatment of
MDA-MB-231 cells with concentrations of 0.1 mM, 1 mM and 10
mM bisphosphonate had little effect on apoptosis. However, MDA-
MB-231 cells showed a 15-fold increase in apoptosis (1515.24 ±
139.33% of control) after treatment with 100 mM zoledronic acid
(P < 0.05). Treatment of MCF-7 cells with 100 mM zoledronic 
acid for 24–96 hours caused a significant time-dependent increase
in apoptosis (P < 0.005) (Figure 2D). In contrast, treatment of cells
with 100 mM EDTA had no effect on tumour cell apoptosis when
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Figure 1 Effect of (A) increasing concentrations of zoledronic acid (0.1–100 mM) on MCF-7 and MDA-MB-231 cell number after incubation for 72 hours and
(B) increasing time of incubation of MCF-7 cells (24–96 hours) with 100 mM zoledronic acid. Results are expressed as percent of control or absolute cell
numbers. Data are the mean and SEM (n = 4). *P < 0.05 compared with control
Table 1 Comparison of the effect of zoledronic acid and EDTA on MCF-7
cell number and apoptosis 
Treatmenta Cell number (´104)b Apoptosis (%) 
Control 24.52 ± 4.3 1.09 ± 0.5 
EDTA (100 mM) 16.08 ± 4.2* 1.30 ± 0.5 
Zoledronic acid (100 mM) 7.00 ± 1.5*† 8.60 ± 1.2* 
aCells were incubated with control, zoledronic acid or EDTA for a total of 72
hours. bResults are expressed as mean ± SEM (n = 4). *P < 0.05 compared
with control. † P < 0.05 compared with EDTA. Zoledronic acid induces apoptosis of breast cancer cells 1129
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compared to control (1.3 ± 0.5% vs 1.09 ± 0.5% respectively)
(Table 1). 
The induction of apoptosis in MCF-7 and MDA-MB-231 cells
by zoledronic acid was confirmed using a fluorescence in situ nick
translation assay. Treatment of MCF-7 cells with a range of zole-
dronic acid concentrations had little effect on apoptosis at 0.1 and
1.0 mM, however, an increase in the proportion of apoptotic cells
was observed with 10 mM and 100 mM zoledronic acid compared
with control (28.7% and 70.7% vs 22.57%, respectively).
Treatment of MDA-MB-231 cells with 0.1–1 mM zoledronic acid
did not cause an increase in apoptosis although treatment with the
10 and 100 mM zoledronic acid resulted in a significant increase in
the proportions of apoptotic cells (126.6% and 126.6% of control)
(data not shown). A significant time-dependent increase in MCF7
cell apoptosis was confirmed when cells were incubated with
100 mM zoledronic acid for 24–96 hours (Table 2). 
Induction of apoptosis of breast cancer cells by
zoledronic acid occurs via inhibition of enzymes of the
mevalonate pathway 
The effects of the addition of intermediates of the mevalonate
pathway on zoledronic acid-induced MCF-7 cell apoptosis were
determined. Analysis of nuclear morphology demonstrated that
treatment of MCF-7 cells with 100 mM zoledronic acid resulted in
a significant increase in apoptosis (18.68 ± 2.5%) compared with
control (0.26 ± 0.1%). The addition of 50 mM farnesol resulted in
a partial inhibition of apoptosis (14.31 ± 0.3%), whereas the addi-
tion of 50 mM geranylgeraniol inhibited apoptosis to levels close
to control (2.27 ± 0.2%) (data not shown). These effects were
confirmed using the in situ nick translation assay (Figure 3).
Table 2 The effects of 100 mM zoledronic acid on MCF-7 cell apoptosis
after 24, 48, 72 and 96 hours of incubation 
Time (hours) Control (%)a Zoledronic acid (%)a
24 19.3 10.4 
48 8.6 24.47 
72 22.67 48.93 
96 14.57 33.07 
aApoptosis was assessed by the in situ nick translation assay and results
were expressed as percentages. 
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Figure 2 Effect of zoledronic acid on apoptosis of MCF-7 and MDA-MB-231 breast cancer cells. Fluorescence micrographs of MCF-7 cells incubated with (A)
vehicle control and (B) 100 mM zoledronic acid for 72 hours demonstrating characteristic changes in nuclear morphology. Cells were cytospun, stained with
4¢-6-diamidino-2-phenyl-indole (DAPI) and examined with a ´ 100 oil immersion objective. Apoptotic nuclei are identified with an asterisk. The effect of (C)
increasing concentrations of zoledronic acid (0.1–100 mM) on MCF-7 and MDA-MB-231 cell apoptosis after 72 hours treatment with 100 mM zoledronic acid.
The effect of increasing time of incubation (24–96 hours) with 100 mM zoledronic acid on MCF-7 apoptosis are shown in panel D. Results are expressed as
percent of the appropriate control or as absolute percentages. Data are the mean ± SE (n = 4). *P < 0.05 compared with control. Treatment of MCF-7 cells with 100 mM zoledronic acid resulted in
a significant increase in apoptosis compared to control (60.57%
and 16.6% apoptosis, respectively). The addition of 100 mM
mevalonate or 50 mM farnesol to zoledronic acid had little effect
on zoledronic acid-induced apoptosis (54.83% and 49.17% respec-
tively). In contrast, the addition of 50 mM geranylgeraniol inhib-
ited zoledronic acid-induced apoptosis to levels below that of
control (12.11%). 
Combined treatment with zoledronic acid and
paclitaxel, at pharmacologically achievable
concentrations, results in synergistic effects on breast
cancer cell number and apoptosis 
In preliminary studies, we investigated the effect of zoledronic
acid in combination with paclitaxel on apoptosis of MCF-7 cells.
Analysis of nuclear morphology demonstrated that combining
zoledronic acid and paclitaxel caused a greater than 2-fold
increase in the proportion of apoptotic MCF-7 cells when
compared with either drug alone (P < 0.02) (data not shown).
The fluorescence DNA labelling assay revealed that treatment
with 10 mM zoledronic acid and 2 mM paclitaxel resulted in a 5-
fold increase in apoptosis (774.8% of control) compared to zole-
dronic acid alone (155.71%) and a 4-fold increase compared to
paclitaxel alone (189.68%) (Figure 4). Since these data suggest
that these compounds may have synergistic effects, a more
detailed isobologram analysis was undertaken. 
The combination of paclitaxel and zoledronic acid was shown to
result in synergistic effects on MCF-7 cell number and apoptosis
(Figure 5(I) and (II)). Dose–response curves were plotted for the
effect of paclitaxel (IA) and zoledronic acid (IB) on cell number
and the IC75 values calculated. The resulting data points were
plotted on an isobologram (IC). The D/D75 ratios for paclitaxel
alone (1) and zoledronic acid alone (1) are shown and connected
by a diagonal line. Points lying on this line indicate a purely 
additive effect. Data points forming a curve lying above this line
indicate antagonism between the 2 drugs whereas a curve lying
below this line suggests a synergistic interaction. The combined
D/D75 ratios derived from the dose–response data clearly formed a
curve which lay below the additive effect line, indicating synergistic
effects between paclitaxel and zoledronic acid on tumour cell
number. 
Combined treatment of MCF-7 cells with paclitaxel and zole-
dronic acid was shown to result in a synergistic increase in tumour
cell apoptosis (Figure 5(II)). Combined drug IC5 values were
determined from dose–response curves plotted for paclitaxel (IIA)
and zoledronic acid (IIB). These were then used to construct an
isobologram (IIC) as described above. Again, the combined D/D5
ratios, when plotted on the isobologram, formed a curve that lay
below the additive effect line indicating a synergistic effect on
tumour cell apoptosis. 
Acute exposure to zoledronic acid causes a reduction
in breast cancer cell number and an increase in
apoptosis 
Zoledronic acid inhibits breast cancer cell proliferation and
induces apoptosis in vitro in a dose- and time-dependent fashion.
However in vivo, breast cancer cells are probably exposed to
micromolar concentrations of bisphosphonates for only a few
hours. Therefore, in order to look at conditions that may more
accurately reflect the situation in vivo, we examined the effects of
acute exposure to 100 mM zoledronic acid on MCF-7 cell number
and apoptosis (Figure 6). 2 hours of exposure to zoledronic acid
1130 SP Jagdev et al 
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Figure 3 Effects of intermediates of the mevalonate pathway on zoledronic
acid-induced apoptosis of MCF-7 cells. Mevalonate and farnesol have little
effect on zoledronic acid-induced apoptosis whereas 50 mM geranylgeraniol
rescues MCF-7 cells from apoptosis induced by zoledronic acid. Results are
expressed as percent of control 
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Figure 4 Effect of combined treatment of MCF-7 cells with 10 mM 
zoledronic acid and 2 nM paclitaxel. Cells were incubated with 10 mM
zoledronic acid in the presence or absence of 2 nM paclitaxel for a total 
of 72 hours. Apoptosis was assessed using the in situ nick translation assay.
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resulted in reduction in cell number to 77.1 ± 19% of control
(P < 0.05). This was associated with an increase in the proportions
of apoptotic cells from 1.23 ± 0.5% in the control samples to
8.05 ± 0.6% in zoledronic acid-treated cells (P < 0.05). 6 and 24
hours of exposure resulted in a reduction in cell number of 44.75 ±
7.9% and 30.04 ± 9.8% of control, respectively (P < 0.05). The
proportions of apoptotic cells at the 6 and 24 hour time points were
similar to that at 2 hours (8.24 ± 0.7% and 8.24 ± 1.1% respec-
tively) (P < 0.05) indicating that acute exposure to zoledronic acid
results in significant induction of apoptosis. The induction of
apoptosis by zoledronic acid at 2, 6 and 24 hours was confirmed
using the in situ nick translation assay. 2 hours of exposure to
100 mM zoledronic acid showed an increase in apoptosis of
236.03% of control. This proportion increased to 289.15% after
6 hours of exposure and 643.62% after 24 hours (values expressed
as percent of appropriate controls). 
DISCUSSION 
In the present study we have shown that zoledronic acid has a
dose-and time-dependent effect on breast cancer cell number in
vitro. These observations are consistent with previous studies that
have demonstrated that bisphosphonates cause a significant 
reduction in osteoclast number (Hughes et al, 1995; Fisher et al,
1999). Importantly, studies in human myeloma cells have shown
that nitrogen-containing bisphosphonates, including zoledronic
acid, also inhibit cell proliferation (Shipman et al, 1997, 1998;
Aparicio et al, 1998; Derenne et al, 1999). The effects of zole-
dronic acid on MCF-7 and MDA-MB-231 cell number were asso-
ciated with concomitant dose- and time-dependent changes in
nuclear morphology that were characteristic of apoptosis (Wyllie
et al, 1980). These effects on tumour cell apoptosis are consistent
with previous reports that have demonstrated the induction of
apoptosis, in macrophages, osteoclasts and myeloma cells, by
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isobologram (IIC) for the interaction between paclitaxel (l) and zoledronic acid (l l). Dose–response results were expressed as percent of control and are
means ± SE. 1132 SP Jagdev et al 
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bisphosphonates such as pamidronate, incadronate, and zoledronic
acid (Hughes et al, 1995; Rogers et al, 1996; Shipman et al, 1997,
1998; Aparicio et al, 1998; Fisher et al, 1999). Although there
were significant differences between the levels of apoptosis
detected by the 2 different techniques, the relative changes induced
by bisphosphonate treatment were similar. The reasons
for the discrepancy between methods are unclear but may reflect
the conservative assessment of nuclear morphology. Alternatively,
the fluorescence in situ nick translation assay may be identifying
cells in an earlier stage of apoptosis. 
In the present study concentrations of 10–100 mM zoledronic
acid for 72 h were required to induce apoptosis of breast cancer
cells. However, bisphosphonates have a high affinity for mineral-
ized bone and localize to bone rapidly, thus in a clinical setting it is
likely that primary breast cancer cells or those in visceral metas-
tases may be exposed to these compounds for shorter periods.
Indeed, peak serum concentrations are likely to be in the range of
1–3 mM and maintained for only a few hours (Berenson et al,
2000). In bone metastases, where osteoclasts are resorbing bone
loaded with bisphosphonate, and thereby releasing it, prolonged
exposure to high local concentrations of the compound would be
predicted (Sato et al, 1991). However, exposure times of 2, 6 and
12 hours may more accurately reflect those seen by cells other than
osteoclasts in vivo. Incubation of MCF-7 cells with 100 mM zole-
dronic acid for these periods resulted in a similar reduction in cell
number and increase in apoptosis, suggesting that acute exposure
is sufficient to have an anti-tumour effect in these cells. This is
consistent with observations from a study in J774 macrophages
which demonstrated a time-dependent increase in caspase-3-like
enzyme activity, associated with apoptosis, when acutely exposed
to nitrogen-containing bisphosphonates (Coxon et al, 1998). 
Importantly, in the clinical arena, bisphosphonates are also used
in combination with chemotherapy or endocrine therapy (Diel 
et al, 1998). Also, studies in animal models of breast cancer
suggest that the anti-tumour activity of bisphosphonates may be
enhanced when they are combined with chemotherapeutic agents
(Yoneda et al, 2000). The present study has shown that treatment
of MCF-7 cells with zoledronic acid and 2 nM paclitaxel, a
concentration readily achievable in the serum of patients (Wilson
et al, 1994), results in an increase in apoptosis above the expected
additive effect. To investigate this more fully and to demonstrate
synergy, the isobologram method was used in our studies. This
method allows for the analysis of the interaction between 2 drugs
and has been used both in vitro and in vivo (Gessner, 1988;
Leonessa et al, 1994). Our dose–response studies and isobologram
analysis showed evidence of synergistic action between paclitaxel
and zoledronic acid on tumour cell number and apoptosis. The
mechanism by which this occurs was not determined but inhibition
of the mevalonate pathway due to zoledronic acid treatment and
the prevention of chromosome segregation and cell division by
paclitaxel may result in a cumulative apoptotic insult. These mech-
anisms require further study both in vitro and in vivo. It would also
be important to investigate possible synergy with other anti-
neoplastic agents, as well as to explore temporal relationships, in
future studies. 
Although zoledronic acid clearly has cytotoxic effects on breast
cancer cells, these may be mediated by their ability to chelate
calcium. However, studies with EDTA, which will also chelate
calcium, demonstrated that this has only a small effect on the
reduction in cell number and remained significantly different from
the effect observed following zoledronic acid treatment. Unlike the
effect on cell number, EDTA treatment did not result in a signifi-
cant increase in apoptosis compared to control suggesting that the
apoptosis induced by zoledronic acid is not mediated by chelation
of calcium. The reasons for the differences in these effects on cell
number and apoptosis are unclear; however, calcium chelation
with EDTA may be having cytostatic effect on breast cancer cells
rather than a cytotoxic effect. Interestingly, MCF-7 and MDA-
MB-231 cells showed different levels of sensitivity to zoledronic
acid, the reasons for which remain unclear. However, this may
reflect the differing expression of p53 as MCF-7 cells express
wild-type p53 whilst MDA-MB-231 cells express a mutant p53
sequence, which may confer increased resistance to apoptotic
stimuli (O’Connor et al, 1997). Alternatively, MDA-MB-231 cells
may produce a number of cytokines or local growth factors that
could act as survival factors and inhibit zoledronic acid-induced
apoptosis (Fromigue and Body, 2000). There may also be differ-
ences, between the cell lines, in the way in which zoledronic acid
is taken up. 
We have also demonstrated that zoledronic acid-induced apop-
tosis of MCF-7 breast cancer cells can be inhibited by addition of
intermediates of the mevalonate pathway, which is consistent with
observations in osteoclasts, macrophages and myeloma cells
(Luckman et al, 1998; Shipman et al, 1998; Fisher et al, 1999).
This pathway has been shown to be important in the post-
translational modification of small GTP-binding proteins
including Ras, by the process of farnesylation, and Rho and Rac by
geranylgeranylation. These proteins are involved in a range of
important cellular processes including proliferation (Ras),
membrane trafficking and cytoskeletal organization (Rho and
Rac). In the present study, the addition of geranylgeraniol, rescued
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Figure 6 Effect of short-term exposure of MCF-7 cells to 100 mM zoledronic
acid. MCF-7 cells were incubated with zoledronic acid for 2, 6, 24 and
72 hours. The media was then replaced and the cells were maintained for a
total of 72 hours. The effects on cell number (n = 4) and apoptosis as
assessed by in situ nick translation assay (NT) and changes in nuclear
morphology (DAPI, n = 4) are shown. Results are expressed as percent of
control and are the mean ± SE. *P < 0.05 compared with contro.l Zoledronic acid induces apoptosis of breast cancer cells 1133
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MCF-7 cells from zoledronic acid-induced apoptosis, whereas the
addition of farnesol only partially inhibited tumour cell death.
Recent observations by Fisher et al suggest that this may also be
the case in osteoclasts where disruption of the cytoskeleton and
loss of the osteoclast ruffled border, as well as apoptosis, are seen
with bisphosphonate treatment (Fisher et al, 1999). However, this
contrasts with previous studies in J774 macrophages and the JJN3
myeloma cells in which bisphosphonate-induced apoptosis could
be prevented by the addition of both geranylgeraniol and farnesol.
The reasons for the differences between these studies are unclear;
however, farnesylated proteins such as Ras may be less important
in breast cancer cell and osteoclast function than in macrophages
and myeloma cells. 
In summary, the data presented in this study strongly suggest
that zoledronic acid can have an important anti-tumour effect in
breast cancer cells in vitro by promoting tumour cell apoptosis. It
is therefore possible that the beneficial effects seen in patients
receiving bisphosphonate therapy may be due to anti-tumour
effects as well as inhibition of osteoclast-mediated bone resorp-
tion. These observations warrant further investigation in vivo in
patients receiving bisphosphonates. 
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